Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | KCNMA1 | Q12791 | 10/20 | 0.64 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612630 | 0.89 | POLB (0.75) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL247350 | 0.89 | POLB (0.75) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL10634763 | 0.87 | POLB (0.73) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL13166882 | 0.86 | POLB (0.76) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL28734394 | 0.84 | POLB (0.72) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL29721853 | 0.84 | POLB (0.72) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL28295632 | 0.84 | KCNMA1 (0.68) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL7719057 | 0.83 | POLB (0.71) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL10628439 | 0.83 | POLB (0.67) | POLBMEN1KMT2AHPGDALOX15 | |
| SCHEMBL9170975 | 0.82 | POLB (0.71) | POLBMEN1KMT2AHPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2007-02-22 | — | — | US | disclosed |
| WO-2005037196-A2 | SUBSTITUTED 2-ARYLMETHYLENE-N-ARYL-N'-ARYL-MALONAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043076-A1 | Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as activators of caspases and inducers of apoptosis | CASP14, CASP2, CASP3 | POLB 3544/4885MEN1 2893/4885KMT2A 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.